Is Gastrointestinal Stromal Tumor Cancerous?
Title: Is Gastrointestinal Stromal Tumor Cancerous?Category: Diseases and ConditionsCreated: 5/13/2022 12:00:00 AMLast Editorial Review: 5/13/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 13, 2022 Category: Cancer & Oncology Source Type: news

Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
CAMBRIDGE, Mass., Nov. 1, 2021 -- (Healthcare Sales & Marketing Network) --Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercial... Biopharmaceuticals, Oncology, FDA Theseus Pharmaceuticals, targeted oncology, gastrointestinal stromal tumors (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2021 Category: Pharmaceuticals Source Type: news

Telehealth Took Off During the Pandemic. Now, Battles Over State Lines and Licensing Threaten Patients ’ Options
Televisits for medical care took off during the worst days of the pandemic, quickly becoming commonplace. Throughout, it’s probably seemed like it doesn’t matter what state the provider of these telehealth services is located. But that’s only because most states, along with the U.S. Centers for Medicare & Medicaid Services, temporarily waived rules requiring licensed clinicians to hold a valid license in the state where their patient is located. Now states are rolling back many of those pandemic workarounds—meaning the ability to conduct certain virtual appointments may be nearing an end. Johns ...
Source: TIME: Health - August 26, 2021 Category: Consumer Health News Authors: Julie Appleby / Kaiser Health News Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

FDA approves ripretinib for advanced gastrointestinal stromal tumor
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Founded by pioneers of targeted oncology, Theseus is developing best-in-class TKIs to overcome cancer resistance Presentation at AACR highlights THE-630, the Company's next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST) BO... Biopharmaceuticals, Oncology, Venture Capital Theseus Pharmaceuticals, targeted oncology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 13, 2021 Category: Pharmaceuticals Source Type: news

Near-Infrared Imaging for Tumors Deep in Tissue, Such as GISTs Near-Infrared Imaging for Tumors Deep in Tissue, Such as GISTs
Near-infrared hyperspectral imaging combined with machine learning may hold promise for identifying deep-tissue gastrointestinal stromal tumors (GISTs).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Chatter between cell populations drives progression of gastrointestinal tumors
(University of California - San Diego) Researchers at University of California San Diego School of Medicine identified new therapeutic targets for gastrointestinal stromal tumors (GISTs) that could lead to new treatment options for patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2021 Category: International Medicine & Public Health Source Type: news

Deep Vision: Near-infrared imaging and machine learning can identify hidden tumors
(Tokyo University of Science) Gastrointestinal stromal tumors are tumors of the digestive tract that grow underneath the mucus layer covering our organs. Because they are deep inside the tissue, these " submucosal tumors " are difficult to detect and diagnose, even with a biopsy. Now, researchers from Japan have developed a novel minimally invasive and accurate method using infrared imaging and machine learning to distinguish between normal tissue and tumor areas. This technique has a strong potential for widespread clinical use. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 2, 2021 Category: Cancer & Oncology Source Type: news

Survival Rate for Gastrointestinal Stromal Tumors
What Is the Survival Rate for Gastrointestinal Stromal Tumors? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 27, 2021 Category: General Medicine Source Type: news

Genetic testing cost effective for newly diagnosed GIST
(University of California - San Diego) UC San Diego School of Medicine researchers reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic gastrointestinal stromal tumors (GIST), a rare type of cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2020 Category: Cancer & Oncology Source Type: news

Blueprint Medicines Announces European Commission Approval of AYVAKYT(R) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
CAMBRIDGE, Mass., Sept. 25, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that ... Biopharmaceuticals, Regulatory Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 25, 2020 Category: Pharmaceuticals Source Type: news

Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research and Development
Newly created role to oversee R&D organization and advance precision medicine portfolio vision CAMBRIDGE, Mass., Sept. 1, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company foc... Biopharmaceuticals, Personnel Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 1, 2020 Category: Pharmaceuticals Source Type: news

Ripretinib Extends Survival When All Else Fails in Advanced GIST Ripretinib Extends Survival When All Else Fails in Advanced GIST
Treatment with oral ripretinib significantly prolonged survival in patients with advanced gastrointestinal stromal tumors (GIST) who did not respond or were intolerant to three other tyrosine-kinase inhibitors in the INVICTUS study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Three Years of Imatinib May Halve Death Rate in GIST Three Years of Imatinib May Halve Death Rate in GIST
Giving patients with high-risk gastrointestinal stromal tumors imatinib for 3 years rather than 1 year may reduce 10-year mortality by half, say German and Finnish investigators.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson
CARY, N.C., June 4, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCKTM (ripretinib) for the treatment of adult patients with advanced gastrointestinal ... (Source: McKesson News)
Source: McKesson News - June 4, 2020 Category: Information Technology Source Type: news